# Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)

> **NCT02999087** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Groupe Oncologie Radiotherapie Tete et Cou** · enrollment: 707 (actual)

## Conditions studied

- HNSCC

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** avelumab
- **DRUG:** Cisplatin
- **RADIATION:** IMRT

## Key facts

- **NCT ID:** NCT02999087
- **Lead sponsor:** Groupe Oncologie Radiotherapie Tete et Cou
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-09-14
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 707 (ACTUAL)
- **Last updated:** 2025-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02999087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02999087, "Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02999087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*